RxDoctor Payments Data

Yonina Murciano-Goroff, MD

Internal Medicine · New York, NYNPI 1952782401

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by AbbVie at 56.3% of the total. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,149in general payments, 2019–2025

Across 16 payments — averaging $321.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Eli Lilly$425
$3,022,792in research payments, 2019–2025

Across 341 payments — averaging $8864.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.9M
  • AbbVie$904K
  • Mirati Therapeutics, Inc.$133K
  • E.r. Squibb & Sons, L.L.C.$100K
  • Taiho Oncology, Inc.$9K

What the payments were for

  • Consulting fees$2,90056%
  • Travel & lodging$1,74334%
  • Food & beverage$50610%

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie1$2,900
AstraZeneca13$1,824
Eli Lilly2$425

How this compares

$5,149 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,166
Medicare patients
90
Services billed
226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →